Alnylam Pharmaceuticals reported $2.48B in Debt for its fiscal quarter ending in September of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 73.85M 23.06M Jun/2026
Agios Pharmaceuticals USD 31.17M 4.57M Jun/2026
Alnylam Pharmaceuticals USD 2.48B 1.21B Sep/2026
Amgen USD 57.3B 19M Jun/2026
Arrowhead Research USD 983.69M 5.77M Jun/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
BioMarin Pharmaceutical USD 4.19B 11.99M Sep/2026
Incyte USD 38.27M 1.16M Jun/2026
Ionis Pharmaceuticals USD 1.77B 141M Sep/2026
Moderna USD 1.29B 11M Jun/2026
Neurocrine Biosciences USD 392.3M 9.5M Sep/2026
Novartis USD 48.31B 1.31B Sep/2026
PTC Therapeutics USD 2.84B 2.15B Sep/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 23.58B 3.56B Jun/2026
Sarepta Therapeutics USD 857.36M 188.48M Sep/2026
Takeda JPY 4.58T 364.32B Sep/2026
Tectonic Therapeutic USD 876K 115K Dec/2024
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 6.48B 4.5B Sep/2026
Xencor USD 170.11M 5.06M Jun/2026